This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Asia
20 - 22 October, 2025
Presented in Japan Standard TimeThe Westin Miyako Kyoto

Delivered as a Hybrid Event

Dr. Wei Yan, PhD
CEO at Sound Biologics
Speaker

Profile

Wei Yan, Ph.D., CEO of Sound Biologics. Wei cofounded the company in 2015 and led the development of MabPair Technology. Under his leadership, Sound Biologics has successfully grown into a clinical stage company with unique technology platforms and a robust pipeline. The first product of the company, PSB205/QL1706 was approved by NMPA in China in 2024. Wei has over 25 years of industry experience in developing antibody based biotherapeutics. Prior to founding Sound Biologics, he was Director of Antibody Engineering at Amgen Seattle site. During his 14 year-tenure at Amgen and Immunex, Wei and his colleagues engineered many molecules in the pipeline and developed novel technologies that enable the production of bispecific antibodies, monovalent antibodies and antibodies with enhanced effector functions. Wei was co-inventor of more than 15 issued patents or patent applications. He received his B.S. degree from Peking University in China and Ph.D. in Molecular and Cell Biology from the joint program of Cornell University Medical College and Memorial Sloan Kettering Cancer Center.